196 related articles for article (PubMed ID: 36119534)
21. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
22. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
23. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
24. A Prognostic Pyroptosis-Related lncRNAs Risk Model Correlates With the Immune Microenvironment in Colon Adenocarcinoma.
Xia F; Yan Y; Shen C
Front Cell Dev Biol; 2021; 9():811734. PubMed ID: 34966747
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
26. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
Front Oncol; 2021; 11():663263. PubMed ID: 34123820
[TBL] [Abstract][Full Text] [Related]
27. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
28. Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma.
Zhang J; Wu Y; Mu J; Xin D; Wang L; Fan Y; Zhang S; Xu Y
Front Oncol; 2022; 12():954226. PubMed ID: 36203430
[TBL] [Abstract][Full Text] [Related]
29. Action of m6A-related gene signatures on the prognosis and immune microenvironment of colonic adenocarcinoma.
Shugao H; Yinhang W; Jing Z; Zhanbo Q; Miao D
Heliyon; 2024 Jun; 10(11):e31441. PubMed ID: 38845921
[TBL] [Abstract][Full Text] [Related]
30. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
31. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
32. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
34. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
35. M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Xu G; Ji Y; Wang L; Xu H; Shen C; Ye H; Yang X
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992083
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
[TBL] [Abstract][Full Text] [Related]
37. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma.
Zhou X; Zhang H; Duan Y; Zhu J; Dai H
J Clin Lab Anal; 2023 Jan; 37(1):e24813. PubMed ID: 36525280
[TBL] [Abstract][Full Text] [Related]
38. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response.
Li C; Zhang K; Gong Y; Wu Q; Zhang Y; Dong Y; Li D; Wang Z
Front Pharmacol; 2023; 14():1200054. PubMed ID: 37377924
[No Abstract] [Full Text] [Related]
39. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
40. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
